Literature DB >> 11112434

PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells.

A Iguchi1, I Kitajima, M Yamakuchi, S Ueno, T Aikou, T Kubo, K Matsushima, N Mukaida, I Maruyama.   

Abstract

Interleukin-8 (IL-8) mRNA was constitutively expressed in human hepatoma cell line, HepG2 and in human hepatocellular carcinoma (HCC), which often form hypervascular tumors. The sequence 5'-AGGAAG-3' at -137 to -132 bp of IL-8 promoter was shown to be polyomavirus enhancer A binding protein-3 (PEA3) binding site, which can cooperate with activator protein-1 (AP-1). Both PEA3 and AP-1 are essential for constitutive IL-8 expression in HepG2 cells, determined by promoter assays. Moreover, PEA3 and IL-8 proteins coexisted in HCC tissues, but not in uninvolved liver tissues. It is possible PEA3 may have important roles in tumor progression and in angiogenesis in HCC. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112434     DOI: 10.1006/bbrc.2000.3925

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Tumor necrosis factor alpha-induced interleukin-8 production via NF-kappaB and phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis in human hepatocytes.

Authors:  Yosuke Osawa; Masahito Nagaki; Yoshiko Banno; David A Brenner; Takahiko Asano; Yoshinori Nozawa; Hisataka Moriwaki; Shigeru Nakashima
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter.

Authors:  Zhao-Zhong Su; Devanand Sarkar; Luni Emdad; Gregory J Duigou; Charles S H Young; Joy Ware; Aaron Randolph; Kristoffer Valerie; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

3.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas.

Authors:  Peirong Lu; Yasunari Nakamoto; Yoko Nemoto-Sasaki; Chifumi Fujii; Hui Wang; Minako Hashii; Yasukazu Ohmoto; Shuichi Kaneko; Kenichi Kobayashi; Naofumi Mukaida
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 5.  Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.

Authors:  Michael Hedvat; Luni Emdad; Swadesh K Das; Keetae Kim; Santanu Dasgupta; Shibu Thomas; Bin Hu; Shan Zhu; Rupesh Dash; Bridget A Quinn; Regina A Oyesanya; Timothy P Kegelman; Upneet K Sokhi; Siddik Sarkar; Eda Erdogan; Mitchell E Menezes; Praveen Bhoopathi; Xiang-Yang Wang; Martin G Pomper; Jun Wei; Bainan Wu; John L Stebbins; Paul W Diaz; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Anticancer Agents Med Chem       Date:  2012-11       Impact factor: 2.505

6.  NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

Authors:  Anthony G Clementz; Allison Rogowski; Kinnari Pandya; Lucio Miele; Clodia Osipo
Journal:  Breast Cancer Res       Date:  2011-06-14       Impact factor: 6.466

7.  Induction of interleukin-8 by Naegleria fowleri lysates requires activation of extracellular signal-regulated kinase in human astroglial cells.

Authors:  Jong-Hyun Kim; Hae-Jin Sohn; Sang-Hee Lee; Daeho Kwon; Ho-Joon Shin
Journal:  Parasitol Res       Date:  2012-03-13       Impact factor: 2.289

8.  Hypoxia-induced preadipocyte factor 1 expression in human lung fibroblasts through ERK/PEA3/c-Jun pathway.

Authors:  Wun-Hao Cheng; Chia-Ling Chen; Jing-Yun Chen; Chien-Huang Lin; Bing-Chang Chen
Journal:  Mol Med       Date:  2021-07-06       Impact factor: 6.354

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.